Digital low-density parity-check(LDPC) decoders can hardly meet the power-limits brought by the new application scenarios. The analog LDPC decoder, which is an application of the analog computation technology, is cons...Digital low-density parity-check(LDPC) decoders can hardly meet the power-limits brought by the new application scenarios. The analog LDPC decoder, which is an application of the analog computation technology, is considered to have the potential to address this issue to some extent. However, due to the lack of automation tools and analog stopping criteria, the analog LDPC decoders suffer from costly handcraft design and additional decoding delay, and are not feasible to practical applications. To address these issues, a decoder architecture using reusable building blocks is designed to lower the handcraft design, and a probability stopping criterion that is specially designed for analog decoder is further planned and implemented to reduce the decoding delay. Then, a(480,240) CMOS analog LDPC decoder is designed and fabricated in a 0.35-μm CMOS technology. Experimental results show that the decoder prototype can achieve 50 Mbps throughput when the power consumption is about 86.3m W, and the decoding delay can be reduced by at most 93% compared with using the preset maximum decoding delay in existing works.展开更多
Finding the optimal dose combination in two-agent dose-finding trials is challenging due to limited sample sizes and the extensive range of potential doses.Unlike traditional chemotherapy or radiotherapy,which primari...Finding the optimal dose combination in two-agent dose-finding trials is challenging due to limited sample sizes and the extensive range of potential doses.Unlike traditional chemotherapy or radiotherapy,which primarily focuses on identifying the maximum tolerated dose(MTD),therapies involving targeted and immune agents facilitate the identifica-tion of an optimal biological dose combination(OBDC)by simultaneously evaluating both toxicity and efficacy.Cur-rently,most approaches to determining the OBDC in the literature are model-based and require complex model fittings,making them cumbersome and challenging to implement.To address these challenges,we developed a novel model-as-sisted approach called uTPI-Comb.This approach refines the established utility-based toxicity probability interval design by integrating a strategically devised zone-based local and global candidate set searching strategy,which can effectively optimize the decision-making process for two-agent dose escalation or de-escalation in drug combination trials.Extensive simulation studies demonstrate that the uTPI-Comb design speeds up the dose-searching process and provides substantial improvements over existing model-based methods in determining the optimal biological dose combinations.展开更多
基金supported in part by the National Natural Science Foundation of China(No.61601027)the Opening Fund of the Space Objective Measure Key Laboratory(No.2016011)
文摘Digital low-density parity-check(LDPC) decoders can hardly meet the power-limits brought by the new application scenarios. The analog LDPC decoder, which is an application of the analog computation technology, is considered to have the potential to address this issue to some extent. However, due to the lack of automation tools and analog stopping criteria, the analog LDPC decoders suffer from costly handcraft design and additional decoding delay, and are not feasible to practical applications. To address these issues, a decoder architecture using reusable building blocks is designed to lower the handcraft design, and a probability stopping criterion that is specially designed for analog decoder is further planned and implemented to reduce the decoding delay. Then, a(480,240) CMOS analog LDPC decoder is designed and fabricated in a 0.35-μm CMOS technology. Experimental results show that the decoder prototype can achieve 50 Mbps throughput when the power consumption is about 86.3m W, and the decoding delay can be reduced by at most 93% compared with using the preset maximum decoding delay in existing works.
基金This work was supported by the Natural Science Foundation of Anhui Province(2022AH050703)the National Natural Science Foundation of China(11671375).
文摘Finding the optimal dose combination in two-agent dose-finding trials is challenging due to limited sample sizes and the extensive range of potential doses.Unlike traditional chemotherapy or radiotherapy,which primarily focuses on identifying the maximum tolerated dose(MTD),therapies involving targeted and immune agents facilitate the identifica-tion of an optimal biological dose combination(OBDC)by simultaneously evaluating both toxicity and efficacy.Cur-rently,most approaches to determining the OBDC in the literature are model-based and require complex model fittings,making them cumbersome and challenging to implement.To address these challenges,we developed a novel model-as-sisted approach called uTPI-Comb.This approach refines the established utility-based toxicity probability interval design by integrating a strategically devised zone-based local and global candidate set searching strategy,which can effectively optimize the decision-making process for two-agent dose escalation or de-escalation in drug combination trials.Extensive simulation studies demonstrate that the uTPI-Comb design speeds up the dose-searching process and provides substantial improvements over existing model-based methods in determining the optimal biological dose combinations.
